- Conditions
- Cholecystitis
- Interventions
- Cholecystectomy visualization
- Other
- Lead sponsor
- Florida Hospital Tampa Bay Division
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 719
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Biliary Atresia
- Interventions
- Ultrasound Shear Wave Elastography
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 3 Months
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Stanford, California • Ann Arbor, Michigan • Cincinnati, Ohio + 1 more
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Biliary Cancer
- Interventions
- Tremelimumab, RFA, TACE, Cryoablation
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Gallbladder Cancer, Stage IIIB Hilar Cholangiocarcinoma, Stage IV Ampulla of Vater Cancer, Stage IVA Gallbladder Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVA Pancreatic Cancer, Stage IVB Gallbladder Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Stage IVB Pancreatic Cancer
- Interventions
- ADH-1, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Malignant Neoplasm, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- trastuzumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 19
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- bortezomib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- Obeticholic Acid (OCA), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- lapatinib ditosylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Alagille Syndrome
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Primary Biliary Cholangitis
- Interventions
- CNP-104, Placebo
- Drug
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Coronado, California • Lancaster, California • Sacramento, California + 16 more
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- BAY2757556 (Larotrectinib, Vitrakvi)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 18
- States / cities
- Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
- Conditions
- Cholelithiasis, Biliary Dyskinesia
- Interventions
- NOTES Transvaginal Cholecystectomy
- Procedure
- Lead sponsor
- Baystate Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Alagille Syndrome
- Interventions
- maralixibat
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Months and older
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Redwood City, California • San Francisco, California + 11 more
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Other Solid Tumors
- Interventions
- BL-M05D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Interventions
- dolastatin 10
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Primary Biliary Cholangitis, PBC
- Interventions
- Volixibat, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 44
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 38 more
- Conditions
- Cholestasis, Extrahepatic
- Interventions
- WallFlex™ Biliary Fully Covered Metal Stent placement
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- San Francisco, California • Aurora, Colorado • Minneapolis, Minnesota + 7 more
- Conditions
- Biliary Atresia
- Interventions
- Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Holterman, Ai-Xuan, M.D.
- Individual
- Eligibility
- 2 Weeks to 180 Days
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 23 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
- Interventions
- remove Mn from PN if evidence of increased brain Mn on MRI
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 30 Days to 12 Months
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- NGM282
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Coronado, California • Detroit, Michigan + 3 more
- Conditions
- Cancer
- Interventions
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
- Genetic · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon